Cashless Warrant Exercises: What Happens at a Sale or IPO

A warrant gives a venture lender some upside exposure to the company's equity, on top of the interest they're already earning on the loan, as compensation for the risk of lending to an early-stage or asset-light company. It's typically for a small percentage of the company's fully diluted shares, priced at a strike close to the valuation of the company's most recent financing round, and it usually stays exercisable for years after the loan itself is repaid.

In a cash exercise, the warrant holder pays the strike price in full for each share and receives that full number of shares in return. In a cashless exercise, the holder doesn't pay anything; instead, they receive fewer shares than the warrant technically covers, with the number reduced so that the value of the shares received equals what they would have earned had they paid cash and immediately sold at the current price.

For the company, this means less overall dilution than a cash exercise for the same warrant, since fewer net shares are issued, but it also means the company never receives the cash that a cash exercise would have brought in.

The formula nets the current fair value per share against the strike price, then divides that gain by the current fair value to find what fraction of the full warrant converts into actual shares. Say a warrant covers a set number of shares at a strike price well below the company's current value; the holder effectively forfeits enough of the warrant's face amount to cover the strike price, using the built-in value of the shares themselves rather than outside cash, and walks away with the remaining shares.

The exact mechanics are spelled out in the warrant agreement's net exercise formula, so read that clause directly rather than assuming a standard calculation applies, since minor differences in wording change the result.

The formula needs a current fair value per share, which is straightforward for a public company with a trading price but genuinely contested for a private one. Warrant agreements typically specify how that value gets determined, often by reference to the most recent financing round, an independent valuation, or a formula tied to the company's board-determined fair value for other purposes like option pricing.

At exercise, especially around an acquisition or IPO where the stakes are highest, this valuation mechanism gets scrutinized closely by both sides, so it's worth having a valuation method you'd be comfortable defending well before the exercise actually happens.

Before you sign, confirm the net exercise formula's exact wording, how fair market value gets determined for a private company, whether the warrant includes anti-dilution adjustments for future down rounds or splits, and how long the warrant remains exercisable after the loan is repaid. Each of these has real cap table consequences years down the line, well after the loan itself is a memory, and they're far easier to negotiate before signing than to revisit once the lender is holding an outstanding warrant.

It also helps to model the warrant's dilution alongside your other outstanding options and convertible instruments rather than in isolation, since a small warrant grant can look trivial on its own but add up meaningfully once stacked against everything else already promised on the cap table.

Terms to confirm before signing the warrant:

• The exact wording of the net exercise formula, which nets fair value per share against the strike price and divides that gain by fair value.
• How fair market value is determined at a private company, such as the latest financing price, an independent valuation, or a board determined value.
• Whether the warrant includes anti-dilution adjustments for future down rounds or stock splits.
• How long the warrant stays exercisable, since terms often run well beyond the loan's own repayment date.